drugset / Trial / NCT06549595
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.
Timeline
- Start
- 2024-08-07
- Primary completion
- 2031-11-26
- Completion
- 2031-11-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bendamustine | Small molecule | — | — |
| Comparator | Cyclophosphamide | Other / unclassified | — | — |
| Comparator | Doxorubicin | Other / unclassified | — | — |
| Comparator | Prednisone | Other / unclassified | — | — |
| Subject | Surovatamig | Protein / enzyme biologic | — | — |
| Comparator | Vincristine | Small molecule | — | — |
| Comparator | Rituximab | Monoclonal antibody | — | — |